KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitReceivables - NetReceivables Refunds
Ratios

Takeda Pharmaceutical (TAK) Accumulated Depreciation & Amortization (2018 - 2020)

Takeda Pharmaceutical has reported Accumulated Depreciation & Amortization over the past 3 years, most recently at $465.4 million for Q1 2020.

  • For Q1 2020, Accumulated Depreciation & Amortization rose 3452.99% year-over-year to $465.4 million; the TTM value through Mar 2020 reached $465.4 million, up 3452.99%, while the annual FY2020 figure was $465.4 million, 3452.99% up from the prior year.
  • Accumulated Depreciation & Amortization was $465.4 million for Q1 2020 at Takeda Pharmaceutical, up from $13.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $465.4 million in Q1 2020 and bottomed at $13.1 million in Q1 2019.
  • The 3-year median for Accumulated Depreciation & Amortization is $134.7 million (2018), against an average of $204.4 million.
  • Year-over-year, Accumulated Depreciation & Amortization crashed 90.28% in 2019 and then skyrocketed 3452.99% in 2020.
  • Over 3 years, Accumulated Depreciation & Amortization stood at $134.7 million in 2018, then crashed by 90.28% to $13.1 million in 2019, then surged by 3452.99% to $465.4 million in 2020.
  • The last three reported values for Accumulated Depreciation & Amortization were $465.4 million (Q1 2020), $13.1 million (Q1 2019), and $134.7 million (Q1 2018) per Business Quant data.